Co-stimulatory bispecific antibodies are gaining momentum, with activity ramping up across key targets such as 4-1BB and CD28, alongside a broader set of emerging receptors shaping the next phase of development.
As the field evolves, key questions remain around how to translate early promise into clinical success, balance efficacy with safety, and differentiate in this competitive field.
Built using data from Beacon Bispecific, this report provides a clear, structured view of where the space stands today and where it’s heading next.
Key questions answered:
- Which co-stimulatory targets are driving momentum and how is the landscape evolving?
- Where is clinical activity accelerating, and which programs are setting the pace?
- How is the competitive and deal-making landscape shaping development strategies?
- What does the next wave of innovation look like, including dual co-stimulation and combination approaches?
- Which promising assets should be on your radar?
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
